BR9913284A - Métodos para administrar peptìdeos insulinotrópicos - Google Patents

Métodos para administrar peptìdeos insulinotrópicos

Info

Publication number
BR9913284A
BR9913284A BR9913284-2A BR9913284A BR9913284A BR 9913284 A BR9913284 A BR 9913284A BR 9913284 A BR9913284 A BR 9913284A BR 9913284 A BR9913284 A BR 9913284A
Authority
BR
Brazil
Prior art keywords
administering
methods
insulinotropic peptides
peptide
glucagon
Prior art date
Application number
BR9913284-2A
Other languages
English (en)
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9913284A publication Critical patent/BR9913284A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Patente de Invenção: <B>"MéTODOS PARA ADMINISTRAR PEPTìDEOS INSULINOTRóPICOS"<D>. A invenção reivindicada refere-se a um método de administrar moléculas de peptídeo-1 tipo glucagon por inalação, um método para tratar diabetes administrando moléculas de peptídeo-1 tipo glucagon por inalação, em um método para tratar hiperglicemia administrando moléculas de peptídeo-1 tipo glucagon por inalação.
BR9913284-2A 1998-08-28 1999-08-24 Métodos para administrar peptìdeos insulinotrópicos BR9913284A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11
PCT/US1999/019348 WO2000012116A1 (en) 1998-08-28 1999-08-24 Method for administering insulinotropic peptides

Publications (1)

Publication Number Publication Date
BR9913284A true BR9913284A (pt) 2001-05-15

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913284-2A BR9913284A (pt) 1998-08-28 1999-08-24 Métodos para administrar peptìdeos insulinotrópicos

Country Status (21)

Country Link
EP (1) EP0997151B1 (pt)
JP (1) JP2002523466A (pt)
KR (1) KR20010073033A (pt)
CN (1) CN1314818A (pt)
AR (1) AR022368A1 (pt)
AT (1) ATE347902T1 (pt)
AU (1) AU764371B2 (pt)
BR (1) BR9913284A (pt)
CA (1) CA2341454A1 (pt)
CO (1) CO5090908A1 (pt)
CZ (1) CZ2001690A3 (pt)
DE (1) DE69934380D1 (pt)
EA (1) EA200100289A1 (pt)
HR (1) HRP20010141A2 (pt)
HU (1) HUP0103369A3 (pt)
IL (1) IL141241A0 (pt)
NO (1) NO20010982L (pt)
PE (1) PE20001031A1 (pt)
PL (1) PL346317A1 (pt)
TR (1) TR200100600T2 (pt)
WO (1) WO2000012116A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GEP20063908B (en) * 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
AU2003257156B2 (en) * 2002-08-01 2007-08-30 Mannkind Corporation Cell transport compositions and uses thereof
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
MX2007002189A (es) 2004-08-23 2008-01-11 Mannkind Corp Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
IN2015DN00888A (pt) 2006-02-22 2015-07-10 Mannkind Corp
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CA2703338A1 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
WO2009155581A1 (en) 2008-06-20 2009-12-23 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX2011007371A (es) 2009-01-08 2011-09-06 Mannkind Corp Metodo para tratar la hiperglucemia con la molecula.
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
BRPI1013154B1 (pt) 2009-06-12 2020-04-07 Mannkind Corp Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
IN2014DN03093A (pt) 2011-10-24 2015-05-15 Mannkind Corp
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN110325657A (zh) 2017-02-21 2019-10-11 杰富意钢铁株式会社 高碳热轧钢板及其制造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances

Also Published As

Publication number Publication date
NO20010982L (no) 2001-04-27
EA200100289A1 (ru) 2001-10-22
AU5584199A (en) 2000-03-21
IL141241A0 (en) 2002-03-10
EP0997151B1 (en) 2006-12-13
AR022368A1 (es) 2002-09-04
NO20010982D0 (no) 2001-02-27
DE69934380D1 (de) 2007-01-25
CA2341454A1 (en) 2000-03-09
TR200100600T2 (tr) 2001-07-23
AU764371B2 (en) 2003-08-14
PE20001031A1 (es) 2000-10-12
HUP0103369A3 (en) 2002-03-28
HUP0103369A2 (hu) 2002-02-28
CN1314818A (zh) 2001-09-26
CO5090908A1 (es) 2001-10-30
PL346317A1 (en) 2002-01-28
HRP20010141A2 (en) 2002-02-28
WO2000012116A1 (en) 2000-03-09
CZ2001690A3 (cs) 2002-04-17
ATE347902T1 (de) 2007-01-15
EP0997151A3 (en) 2000-09-20
JP2002523466A (ja) 2002-07-30
KR20010073033A (ko) 2001-07-31
EP0997151A2 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
BR9913284A (pt) Métodos para administrar peptìdeos insulinotrópicos
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
WO2006024275A3 (de) Erfindung betreffend glp-1 und exendin
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
EP2022505A3 (en) GLP-1, exendin-4, peptide analogs and uses thereof
IL176541A0 (en) Intranasal administration of glucose-regulating peptides
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
NZ527241A (en) Analogues of GLP-1
BR0207700A (pt) Método para tratar a diabete melito em um paciente em necessidade de tal tratamento, e, usos de um derivado de polipeptìdeo de insulina, e de um conjugado de polipeptìdeo de insulina-oligÈmero
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
IL145829A0 (en) Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
SE9802080D0 (sv) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
IL208184A0 (en) Glp-1, and methods for treating diabetes
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
IL146868A0 (en) A pharmaceutical composition containing an igf-i/igfbp-3 complex
WO2003094933A3 (en) Use of lanthanum for the treatment of hypercalcemia and bone metastasis
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
ECSP982593A (es) Nuevo metodo de tratamiento vi
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982534A (es) Nuevo metodo de tratamiento
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.